

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**東北虎藥業股份有限公司**  
**NORTHEAST TIGER PHARMACEUTICAL CO., LTD.\***  
*(A joint stock limited company established in the People's Republic of China)*  
**(Stock Code: 8197)**

**COMPLETION OF ISSUANCE OF  
NEW DOMESTIC SHARES  
UNDER GENERAL MANDATE**

The Board announces that the condition precedent under the Subscription Agreements has been fulfilled and the completion of the Subscription took place on 11 November, 2016. An aggregate of 70,000,000 Subscription Shares have been issued to the Subscribers at the price of RMB0.89 per Subscription Share pursuant to the terms and conditions of the Subscription Agreements.

Reference is made to the announcements (the “**Announcements**”) of the Company dated 13 and 14 July 2016 in relation to the issuance of new Domestic Shares under the General Mandate. Terms defined in the Announcements shall have the same meanings when used herein unless the context requires otherwise.

**COMPLETION OF THE SUBSCRIPTION**

The Board announces that the condition precedent under the Subscription Agreements has been fulfilled and the completion of the Subscription took place on 11 November, 2016. An aggregate of 70,000,000 Subscription Shares have been issued to the Subscribers at the price of RMB0.89 per Subscription Share pursuant to the terms and conditions of the Subscription Agreements.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, each of the Subscribers is an Independent Third Party and is not connected person of the Company (as defined under the GEM Listing Rules). None of the

Subscribers has become a substantial Shareholder (as defined under the GEM Listing Rules) immediately after the completion of the Subscription. The net proceeds from the Subscription is approximately RMB 62,300,000 (equivalent to approximately HK\$71,022,000 <sup>(Note)</sup>) which is intended to be used for business development and general working capital of the Group.

## EFFECTS ON SHAREHOLDING STRUCTURE

The 70,000,000 Subscription Shares represent approximately 8.16% of the total issued share capital of the Company as at the date of this announcement immediately after the completion of the Subscription.

Set out below is the shareholding structure of the Company immediately before and after the completion of the Subscription:

	Immediately before the completion of the Subscription		Immediately after the completion of the Subscription	
	<i>Number of Shares</i>	<i>Approximate % of issued Shares</i>	<i>Number of Shares</i>	<i>Approximate % of issued Shares</i>
<b>Domestic Shares</b>				
Beijing Bao Ying Chuang Fu Investment Management Centre*	398,534,660	50.57	398,534,660	46.45
Guo Feng	137,611,830	17.46	137,611,830	16.04
Zhang Ya Bin	1,618,960	0.21	1,618,960	0.19
Subscriber I	0	0	31,500,000	3.67
Subscriber II	0	0	31,500,000	3.67
Subscriber III	0	0	7,000,000	0.82
Other Shareholders	1,888,790	0.24	1,888,790	0.22
<b>H-Shares</b>				
Public Shareholders	248,400,000	31.52	248,400,000	28.94
<b>Total</b>	<b>788,054,240</b>	<b>100.00</b>	<b>858,054,240</b>	<b>100.00</b>

*Note:* The figures are calculated based on the middle exchange rate of RMB1 to HK\$1.14 as quoted by The People's Bank of China as at 11 November 2016, being the date of this announcement.

By Order of the Board  
東北虎藥業股份有限公司  
**Northeast Tiger Pharmaceutical Co., Ltd.\***  
*Chairman*  
**Wang Shaoyan**

Jilin, the PRC, 11 November , 2016

*As at the date of this announcement, the Company's executive directors are Wang Shaoyan, Cui Bingyan and Qin Haibo; the Company's non-executive directors are Guo Aiqun and Cao Yang and the Company's independent non-executive directors are Zhao Zhen Xing, Chen Youfang and Hui Lai Yam.*

*This announcement, for which the directors of the Company collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors of the Company, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*\* for identification purposes only*